Research article · 15 Apr 2026
Conference abstractPublished 14 Sep 2015
Magnesium (Mg) deficiency worsens and Mg replacement protects against cisplatin-induced kidney injury in non-tumor and tumor-bearing mice
The Feinstein Institute for Medical Research, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Cisplatin is a potent chemotherapy for treating ovarian and other cancers. Cisplatin-induced acute kidney injury (AKI) occurs in ~25% of patients while hypomagnesemia occurs in 90% of patients. Previous studies have implicated magnesium (Mg) status in cisplatin-induced AKI. We explored the effect of Mg deficiency (MgD) (Ã?±Mg supplementation, MgS) in a mouse model of cisplatininduced AKI. In addition, using an ovarian (A2780) tumor xenograft model, we examined the effect of Mg status on cisplatin-induced AKI and the anti-tumor efficacy of cisplatin. In both non-tumor- and tumor-bearing mice, Mg deficiency (MgD) significantly worsened cisplatin-induced AKI (based on BUN, inflammation, apoptosis and histological scores) while MgS significantly protected against cisplatin-induced AKI. Tumor growth was inhibited by cisplatin and further inhibited by MgS on day 22. MgD did not affect tumor growth or cisplatin-mediating tumor killing. Ongoing studies are exploring the role of Mg status in tumor growth and cisplatin-induced AKI in additional tumor models in mice. In summary, MgD worsens and MgS protects against cisplatin-induced AKI as evidenced by improved kidney function and reduced renal inflammation and apoptosis. While improving kidney function, MgS also improved cisplatin-induced tumor killing. Mechanistic studies reveal that MgD increases renal platinum accumulation through regulating cisplatin transporter expression/function in the kidneys; these effects are not observed in the tumor. These findings warrant future large scale studies to assess Mg status and aggressive Mg replacement therapy in cisplatin-treated patients. In addition, assessment of dose, formulation and timing/duration of Mg replacement in cisplatin-treated patients should be considered to promote renoprotection.
Subjects
Nephrology & UrologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Nephrology & Therapeutics.
Brief report · 30 Mar 2026
Renal Fibrosis: Targeting Pathways For New Therapies
Brief report · 30 Mar 2026
SGLT2 Inhibitors: A New Era for Diabetic Kidney Disease
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Nephrology & Therapeutics
- SubjectNephrology & Urology
- BylineArticles whose byline prints “Christine N Metz”
